Document is current
Any future updates will be listed below
-
Authors
Nordlund, David https://orcid.org/0000-0002-6567-8459
Engblom, Henrik
Bonnet, Jean-Louis
Hansen, Henrik Steen
Atar, Dan
Erlinge, David
Ekelund, Ulf
Heiberg, Einar
Carlsson, Marcus
Arheden, Håkan
-
Funding
Funding for this research was provided by:
Skåne County Council's Research and Development Foundation
FP7 Ideas: European Research Council (HEALTH-2010-261034)
- License Information
-
More Information
Article History
Received: 8 January 2019
Accepted: 24 June 2019
First Online: 3 July 2019
Ethics approval and consent to participate
: The MITOCARE trial was approved by the local or regional institutional review boards/ethics committees in each of the 10 respective sites and coordination of the approvals are handled by the safety and ethics monitoring committee []. The CHILL-MI trial was approved by the ethics commission of the medical University of Innsbruck and of the University of Vienna for Austria, the committees of science ethics of the capital region for Denmark, and the ethical review board in Lund for Sweden. The SOCCER trial was approved by the regional Ethical Review Board in Lund (Dnr 2011/258) []. All patients provided written informed consent.
: All patients provided written informed consent.
: Dr. Arheden is a shareholder of Imacor. Drs Arheden, Heiberg, Carlsson, and Engblom consult for Imacor, the core-lab that performed the CMR-analysis for the MITOCARE, CHILL-MI, and SOCCER trials. Dr. Heiberg is the founder and owner of the company Medviso AB, Lund, Sweden. The authors declare that they have no competing interests.
